Dosimetric Analysis of Intracavitary Brachytherapy Applicators: a Practical Study

Overview

Journal Radiat Oncol J

Specialty Oncology

Date 2022 Oct 6

PMID 36200307

Authors

Aijaz A Khan

Anuj Vijay

Shaqul Qamar Wani

Malik M Haq

Affiliations

Soon will be listed here.

Abstract

Purpose: Intracavitary brachytherapy is one of the important methods of gynecological cancer treatment. The effect of attenuation is not considered in the dose calculation method released by the American Association of Physicists in Medicine (AAPM) Task Group No. 43 Report (TG-43). In this study, the effect of high-dose rate (HDR) brachytherapy applicators on dose distribution was measured using Gafchromic films and well-type ionization chamber.

Materials And Methods: A plan created by the treatment planning system was first executed using a well-type ionization chamber with a water equivalent elasto-gel in place for charge collection. Again, same plan was executed using central tandems of various angulations with different diameters of vaginal cylinders and charge collection was measured. For in vitro dose measurements this plan was also executed on tandem and vaginal cylinder assembly with Gafchromic films fixed on the surface of vaginal cylinder.

Results: The results show that the central tandem when used with different vaginal cylinders resulted in increase in effective attenuation of the beam. The central tandem of 300 angulations when used with a 35-mm diameter vaginal cylinder results in maximum attenuation whereas the 0º tandem when used with 20-mm diameter vaginal cylinder results in least attenuation of the beam.

Conclusion: Due to the attenuation by various applicators used in brachytherapy for the treatment of gynecological cancers, it can be concluded that the difference between practical dose and the treatment planning system calculated dose should be considered for the correct estimation of the dose to the target and the organs-at-risk.

Citing Articles

MRI-based volumetric tumor parameters before and during chemoradiation predict tumor recurrence and patient survival in locally advanced cervical cancer: a subgroup analysis of a phase II prospective trial.

Kang H, Kim S, Lee J, Lee H, Kang N, Lee J Int J Clin Oncol. 2024; 29(5):620-628.

PMID: 38530569 DOI: 10.1007/s10147-024-02490-7.

Intensity-Modulated Radiation Therapy for Uterine Cervical Cancer to Reduce Toxicity and Enhance Efficacy - an Option or a Must?: A Narrative Review.

Lee S, Kim A, Lee S, Kim S, Lee J Cancer Res Treat. 2023; 56(1):1-17.

PMID: 37654111 PMC: 10789959. DOI: 10.4143/crt.2023.562.

References

Perez-Calatayud J, Ballester F, Das R, DeWerd L, Ibbott G, S Meigooni A . Dose calculation for photon-emitting brachytherapy sources with average energy higher than 50 keV: report of the AAPM and ESTRO. Med Phys. 2012; 39(5):2904-29. DOI: 10.1118/1.3703892. View

Rose P, Bundy B, Watkins E, Thigpen J, Deppe G, Maiman M . Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999; 340(15):1144-53. DOI: 10.1056/NEJM199904153401502. View

Fellner C, Potter R, Knocke T, Wambersie A . Comparison of radiography- and computed tomography-based treatment planning in cervix cancer in brachytherapy with specific attention to some quality assurance aspects. Radiother Oncol. 2001; 58(1):53-62. DOI: 10.1016/s0167-8140(00)00282-6. View

Gadda I, Khan N, Wani S, Baba M . To evaluate the use of tandem and cylinder as an intracavitary brachytherapy device for carcinoma of the cervix with regard to local control and toxicities. J Cancer Res Ther. 2022; 18(3):740-746. DOI: 10.4103/jcrt.jcrt_243_21. View

Yi M, Li T, Niu M, Luo S, Chu Q, Wu K . Epidemiological trends of women's cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study. Biomark Res. 2021; 9(1):55. PMC: 8261911. DOI: 10.1186/s40364-021-00310-y. View

Parsai E, Zhang Z, Feldmeier J . A quantitative three-dimensional dose attenuation analysis around Fletcher-Suit-Delclos due to stainless steel tube for high-dose-rate brachytherapy by Monte Carlo calculations. Brachytherapy. 2009; 8(3):318-23. DOI: 10.1016/j.brachy.2008.11.012. View

Kapp K, Stuecklschweiger G, Kapp D, Hackl A . Dosimetry of intracavitary placements for uterine and cervical carcinoma: results of orthogonal film, TLD, and CT-assisted techniques. Radiother Oncol. 1992; 24(3):137-46. DOI: 10.1016/0167-8140(92)90372-2. View

Williamson J, Li Z . Monte Carlo aided dosimetry of the microselectron pulsed and high dose-rate 192Ir sources. Med Phys. 1995; 22(6):809-19. DOI: 10.1118/1.597483. View

Vandana S, Sharma S . Long term response stability of a well-type ionization chamber used in calibration of high dose rate brachytherapy sources. J Med Phys. 2010; 35(2):100-3. PMC: 2884301. DOI: 10.4103/0971-6203.62200. View

10.

Sankaranarayanan R, Ferlay J . Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2005; 20(2):207-25. DOI: 10.1016/j.bpobgyn.2005.10.007. View

11.

Ling C, Schell M, Working K, JENTZSCH K, Harisiadis L, Carabell S . CT-assisted assessment of bladder and rectum dose in gynecological implants. Int J Radiat Oncol Biol Phys. 1987; 13(10):1577-82. DOI: 10.1016/0360-3016(87)90327-0. View

12.

Roy S, Subramani V, Singh K, Rathi A, Savita A, Aditi A . Study of the effects of dwell time deviation constraints on inverse planning simulated annealing optimized plans of intracavitary brachytherapy of cancer cervix. J Cancer Res Ther. 2020; 15(6):1370-1376. DOI: 10.4103/jcrt.JCRT_246_18. View

13.

Nag S, Erickson B, Thomadsen B, Orton C, Demanes J, Petereit D . The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2000; 48(1):201-11. DOI: 10.1016/s0360-3016(00)00497-1. View

14.

Rivard M, Coursey B, DeWerd L, Hanson W, Huq M, Ibbott G . Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. Med Phys. 2004; 31(3):633-74. DOI: 10.1118/1.1646040. View

15.

Tyree W, Cardenes H, Randall M, Papiez L . High-dose-rate brachytherapy for vaginal cancer: learning from treatment complications. Int J Gynecol Cancer. 2002; 12(1):27-31. DOI: 10.1046/j.1525-1438.2002.01072.x. View

16.

Rivard M, Butler W, DeWerd L, Huq M, Ibbott G, S Meigooni A . Supplement to the 2004 update of the AAPM Task Group No. 43 Report. Med Phys. 2007; 34(6):2187-205. DOI: 10.1118/1.2736790. View

17.

Taylor R, Rogers D . EGSnrc Monte Carlo calculated dosimetry parameters for 192Ir and 169Yb brachytherapy sources. Med Phys. 2008; 35(11):4933-44. DOI: 10.1118/1.2987676. View

18.

Ballester F, Puchades V, Lluch J, Limami Y, Perez-Calatayud J, Casal E . Technical note: Monte-Carlo dosimetry of the HDR 12i and Plus 192Ir sources. Med Phys. 2002; 28(12):2586-91. DOI: 10.1118/1.1420398. View

19.

A M, M G . Determination of TG-43 Dosimetric Parameters for Photon Emitting Brachytherapy Sources. J Biomed Phys Eng. 2019; 9(4):425-436. PMC: 6709347. DOI: 10.31661/jbpe.v0i0.570. View

20.

Schoeppel S, LaVigne M, Martel M, McShan D, Fraass B, Roberts J . Three-dimensional treatment planning of intracavitary gynecologic implants: analysis of ten cases and implications for dose specification. Int J Radiat Oncol Biol Phys. 1994; 28(1):277-83. DOI: 10.1016/0360-3016(94)90168-6. View